Linezolid Kalceks (Linezolid)

Linezolid is an oxazolidinone antibiotic indicated for serious Gram‑positive bacterial infections.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides effective bacterial clearance in severe cases.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative treatment option when other agents fail.
• Community‑acquired bacterial pneumonia: improves clinical outcomes in patients with Gram‑positive pathogens.
• Skin and soft tissue infections caused by Gram‑positive bacteria: achieves rapid resolution of infection signs and symptoms.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing formation of the initiation complex required for protein synthesis. By inhibiting the early stage of translation, it halts bacterial growth and leads to bacteriostatic activity against most Gram‑positive organisms, including strains resistant to other antibiotic classes. The binding is reversible and specific, allowing selective targeting of bacterial cells while sparing human ribosomes.

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools often occurring early in therapy.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Metallic taste: altered taste perception.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: sensory disturbances in extremities.
• Serotonin syndrome: risk when combined with serotonergic drugs.
• Lactic acidosis: metabolic disturbance with high mortality.
• Optic neuropathy: visual impairment due to optic nerve damage.
• Myelosuppression: bone‑marrow suppression affecting blood cell lines.

Before initiating Linezolid therapy, clinicians should consider several precautionary measures to ensure patient safety.

• Monitor blood counts: check platelet and leukocyte levels regularly.
• Assess renal function: adjust therapy in patients with severe renal impairment.
• Evaluate hepatic status: use cautiously in moderate to severe liver disease.
• Avoid serotonergic agents: discontinue SSRIs, MAO inhibitors, and similar drugs to prevent serotonin syndrome.
• Use with caution in patients with a history of myelosuppression: watch for further hematologic effects.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Linezolid can interact with other medicines, and the significance of these interactions varies.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: may precipitate serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis and serotonin toxicity.
• Tricyclic antidepressants: additive serotonergic effects.
• Meperidine and other opioid analgesics with serotonergic activity: heightened serotonin syndrome risk.
• Tyramine‑rich foods: potential hypertensive reactions due to MAO inhibition.

Moderate Interactions (Monitor Closely)

• Rifampin: induces hepatic enzymes, reducing linezolid plasma concentrations.
• Antacids containing aluminum or magnesium: may affect absorption if given simultaneously.
• Warfarin: monitor INR as linezolid can alter anticoagulant effect.
• Ethanol: may increase risk of hypotension.
• Concomitant use of other myelosuppressive agents: enhance bone‑marrow toxicity.